6533b823fe1ef96bd127f8a4

RESEARCH PRODUCT

Early palliative care of non‑small cell lung cancer in the context of immunotherapy (Review)

subject

description

Abstract. The most common cause of mortality due to malig‑ nant neoplasms in the general population around the world is lung cancer. In the last 10 years, there has been an enormous improvement in the treatment of this disease, mainly due to the immunotherapy that activates the immune system to fight cancer. Patients with metastatic non‑small cell lung cancer are a special group of patients requiring not only cancer treatment but also considerable support in the treatment of cancer‑related problems, as well as comorbidities. Early palliative care is important in this area. In addition, there is certain evidence that medicines most commonly administered in palliative care may lower the efficacy of immunotherapy. The present review article compares information on the prolonging of life after early hospice care, which has become the foundation of current standards of management in patients with metastatic lung cancer, and reports of decreased efficacy of the immu‑ notherapy due to the administration of major palliative care medications.